Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 5/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 3/20 | 0.49 |
| ▸ | ATR | Q13535 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
| ▸ | TTK | P33981 | 3/20 | 0.44 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20074742 | 0.83 | TGFBR1 (0.58) | TGFBR1MAPK14KDRATRHDAC4 | |
| SCHEMBL24307575 | 0.82 | TGFBR1 (0.55) | TGFBR1MAPK14KDRATRHDAC4 | |
| SCHEMBL25946718 | 0.82 | TGFBR1 (0.55) | TGFBR1MAPK14KDRATRHDAC4 | |
| SCHEMBL20074744 | 0.81 | TGFBR1 (0.56) | TGFBR1MAPK14KDRATRHDAC4 | |
| SCHEMBL14924015 | 0.80 | ALDH1A1 (0.51) | HDAC4HDAC6BRD4 | |
| SCHEMBL14082343 | 0.76 | MAPKAPK2 (0.54) | TGFBR1MAPK14ROCK2ROCK1HDAC6 | |
| SCHEMBL6222961 | 0.74 | TGFBR1 (1.00) | TGFBR1MAPK14KDRATRROCK2 | |
| SCHEMBL5956512 | 0.74 | TGFBR1 (0.59) | TGFBR1MAPK14KDRATRHDAC4 | |
| SCHEMBL14082425 | 0.74 | NPC1 (0.59) | MAPK14ROCK2MAPKAPK2DYRK1B | |
| SCHEMBL5907486 | 0.74 | TGFBR1 (0.58) | TGFBR1MAPK14KDRATRROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219453-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2023-08-02 | — | — | EP | disclosed |
| US-20220064187-A1 | SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT | Clavius Pharmaceuticals, LLC. | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064187-A1 | SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT | TGFB1, TGFBR1, TGFB2 | TGFBR1 2/4885MAPK14 589/4885KDR 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.